Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas.

ABSTRACT: The current standard of care for epithelial ovarian cancer does not discriminate between different histologic subtypes (serous, clear cell, endometrioid and mucinous) despite the knowledge that ovarian carcinoma subtypes do not respond uniformly to conventional platinum/taxane-based chemotherapy. Exploiting addictions and vulnerabilities in cancers with distinguishable molecular features presents an opportunity to develop individualized therapies that may be more effective than the current 'one size fits all' approach. One such opportunity is arginine depletion therapy with pegylated arginine deiminase, which has shown promise in several cancer types that exhibit low levels of argininosuccinate synthetase including hepatocellular and prostate carcinoma and melanoma. Based on the high level

SUBMITTER: Cheon DJ 

PROVIDER: S-EPMC4858122 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature